INTRODUCTION {#s1}
============

The colon is an embryological derivative of the midgut and hindgut separately, and thus the right-sided colon, the left-sided colon, and the rectum each have different anatomical and physiological features. Evidence shows that tumors arising from right colon have distinct clinical and biological characteristics compared with tumors of the left colon or rectum \[[@R1]-[@R6]\]. Right-sided colorectal cancer (RCRC) is generally characterized by being more common in women, and associated with Lynch syndrome, the serrated pathway, Mitogen-activated protein kinase signaling, microsatellite instability-high (MSI-H), deficiency of mismatch repair genes, CpG island methylation, and *KRAS* and *BRAF* mutations \[[@R7]-[@R10]\]. Left-sided colorectal cancer (LCRC) is more common in men, and associated with familial adenomatous polyposis syndrome, Wnt and EGFR signaling, chromosomal instability, *ERBB1* and *ERBB2* amplifications, and *APC*, *p53*, and *NRAS* mutations \[[@R10], [@R11]\]. Based on these molecular differences, sidedness of CRC is thought to be associated with efficacy of chemotherapy and targeted therapy.

The monoclonal antibodies cetuximab and panitumumab are epidermal growth factor receptor (EGFR) inhibitors that block downstream signaling of the EGFR pathway. Randomized phase III clinical trials have shown a survival benefit of these anti-EGFR monoclonal antibodies in *RAS* wild-type metastatic CRC \[[@R12]-[@R14]\]; however, tumor location has not traditionally been included as a stratification criterion in clinical trials. Recently, several retrospective, unplanned analyses examined primary tumor sidedness and revealed that anti-EGFR therapy clearly benefitted patients with LCRC, whereas patients with RCRC derived limited benefit \[[@R15]-[@R17]\]. Consequently, while these analyses were limited by low numbers of RCRC patients, the related imbalance between groups, and no randomization; primary tumor sidedness of CRC has emerged as new predictive marker for efficacy of anti-EGFR therapy.

The mechanism of resistance to anti-EGFR therapy in patients with RCRC has not been fully elucidated. Although *RAS* mutations are established biomarkers of efficacy to anti-EGFR therapy, anti-EGFR therapy is not effective for all patients with a *RAS* wild-type tumor \[[@R18]-[@R21]\]. Genetic alterations in tyrosine kinase (TK) receptors, the RAS pathway (other than *KRAS* and *NRAS* mutations), and the PI3K pathway are other possible mechanisms of resistance to anti-EGFR therapy \[[@R22], [@R23]\]. While the most clinically important alterations, such as *KRAS*, *NRAS*, and *BRAF* mutations, have been widely analyzed among patients with metastatic CRC, the other alterations have not been widely studied.

Next-generation sequencing projects, such as The Cancer Genome Atlas, have profiled genomic changes in many cancers including CRC \[[@R24]\]. We have similarly reported a genomic analysis of Japanese CRC patients using comprehensive genomic sequencing (CGS) \[[@R25], [@R26]\]. CGS detects gene mutations and copy number alterations in TK receptors, and the RAS and PI3K pathway in a single assay. In the present analysis, we hypothesized that RCRC more frequently harbors genetic alterations associated with resistance to anti-EGFR therapy compared with LCRC. To test this hypothesis, we investigated these genetic alterations using CGS.

RESULTS {#s2}
=======

Association between primary tumor sidedness and clinicopathological characteristics {#s2_1}
-----------------------------------------------------------------------------------

Fifty-six patients (28%) and 145 patients (72%) had RCRC and LCRC, respectively (Figure [1](#F1){ref-type="fig"}). Histopathological grade 3 was significantly associated with RCRC (*P* \< 0.001; Table [1](#T1){ref-type="table"}). Medullary type, mucinous type, and MLH1/MSH2 status were significantly associated with RCRC (*P* = 0.022, *P* = 0.007, and *P* = 0.024, respectively; Table [2](#T2){ref-type="table"}).

![Primary tumor locations in right-sided colorectal cancer and left-sided colorectal cancer\
RCRC, right-sided colorectal cancer; LCRC, left-sided colorectal cancer.](oncotarget-08-93567-g001){#F1}

###### Association between primary tumor sidedness and clinicopathological characteristics (N = 201)

                              Primary tumor sidedness   *P*-value   
  --------------------------- ------------------------- ----------- ----------
  Age (years)                                                       
   \< 65                      22                        78          0.065
   ≥ 65                       34                        67          
  Sex                                                               
   Male                       29                        55          0.074
   Female                     27                        90          
  Tumor size (mm)                                                   
   \< 50                      23                        65          0.630
   ≥ 50                       33                        80          
  T category                                                        
   T1, 2                      6                         18          0.739
   T3, 4                      50                        127         
  Histopathological grading                                         
   G1, 2                      31                        116         \< 0.001
   G3                         25                        29          
  Lymphatic invasion                                                
   Absence                    18                        61          0.196
   Presence                   38                        84          
  Venous invasion                                                   
   Absence                    10                        38          0.213
   Presence                   46                        107         
  N category                                                        
   N0                         13                        46          0.235
   N1, 2                      43                        99          
  M category                                                        
   M0                         22                        68          0.331
   M1                         34                        77          

###### Primary tumor sidedness and pathological and genetic characteristics related with deficiency of mismatch repair genes (N = 201)

                                      Primary tumor sidedness   *P*-value   
  ----------------------------------- ------------------------- ----------- -------
  Medullary type                                                            
   Yes                                52                        144         0.022
   No                                 4                         1           
  Mucinous type                                                             
   Yes                                47                        139         0.007
   No                                 9                         6           
  Signet ring type                                                          
   Yes                                55                        143         0.999
   No                                 1                         2           
  Tumor infiltrating lymphocytes^a^                                         
   Yes                                13                        23          0.223
   No                                 43                        122         
  MLH1/MSH2 status                                                          
   Normal                             22                        69          0.013
   Abnormal                           10                        9           
  Hypermutated phenotype                                                    
   Hypermutated                       10                        7           0.008
   Non-hypermutated                   46                        138         

^a^ Cut-off value = 10 lymphocytes/5 high power fields.

Association between primary tumor sidedness and genetic alterations evaluated using CGS {#s2_2}
---------------------------------------------------------------------------------------

CGS of the 415-gene panel in our cohort of 201 patients detected genetic alterations in 268 genes ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Mutations in *KRAS*, *PIK3CA*, *RNF43*, *BRAF*, *ACVR2A*, *MSH6*, and *PALB2* were significantly associated with RCRC (*P* = 0.047, *P* = 0.014, *P* = 0.039, *P* \< 0.001, *P* = 0.003, *P* = 0.016, and *P* = 0.001, respectively; Figure [2](#F2){ref-type="fig"}), and mutations in *APC*, *TP53* and *PTCH1* were significantly associated with LCRC (*P* = 0.010, *P* = 0.005, and *P* = 0.036, respectively; Figure [2](#F2){ref-type="fig"}). The hypermutated tumor was significantly associated with RCRC (*P* = 0.008; Table [2](#T2){ref-type="table"}). Genetic alterations found in the 12 genes associated with resistance to anti-EGFR therapy (TK receptors: *ERBB2*, *MET*, *EGFR*, *FGFR1*, and *PDGFRA*; RAS pathway: *KRAS*, *NRAS*, *HRAS*, *BRAF*, and *MAPK2K1*; and PI3K pathway: *PTEN* and *PIK3CA*) are detailed in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}. Of the 201 patients, 154 harbored one or more genetic alterations in these 12 genes with 80, 63, 8, 2, and 1 patients had 1, 2, 3, 4, and 5 gene alterations, respectively. Of the 56 RCRC patients, 6 (11%) were wild-type in all 12 genes (termed "all wild-type"); while 41 of 145 patients (28%) of LCRC were "all wild-type" (*P* = 0.009; Figure [3](#F3){ref-type="fig"}, Table [3](#T3){ref-type="table"}).

![Distribution of genetic alterations in right-sided and left-sided colorectal cancer\
Dark bars indicate genes with a significant difference (*P* \< 0.05, two-tailed Fisher's exact test or Chi-squared test) in the frequency of genetic alterations compared with other-sided donors. Light bars indicate genes that are not significantly different (^\*^, *P* \< 0.05; ^\*\*^, *P* \< 0.01). The genes associated with anti-EGFR resistance were highlighted.](oncotarget-08-93567-g002){#F2}

![Percentage of genetic alterations associated with resistance to anti-EGFR therapy in right-sided colorectal cancer and left-sided colorectal cancer\
Genetic alterations in TK receptors (*ERBB2, MET, EGFR, FGFR1*, and *PDGFRA*), RAS pathway (*KRAS, NRAS, HRAS, BRAF*, and *MAPK2K1*), and PI3K pathway (*PTEN* and *PIK3CA*) were evaluated using comprehensive genomic sequencing of the 415-gene panel. Patients who had no alterations in all 12 genes were defined as "all wild-type". RCRC, right-sided colorectal cancer; LCRC, left-sided colorectal cancer.](oncotarget-08-93567-g003){#F3}

###### Association between primary tumor sidedness and gene alterations of TK receptors/RAS pathway/PI3K pathway (N = 201)

                                                         Primary tumor sidedness   *P*-value   
  ------------------------------------------------------ ------------------------- ----------- ----------
  *ERBB2* status                                                                               
   Wild-type                                             54                        132         0.243
   Mutant^a^                                             2                         13          
  *MET* status                                                                                 
   Wild-type                                             55                        139         0.676
   Mutant^a^                                             1                         6           
  *EGFR* status                                                                                
   Wild-type                                             56                        141         0.578
   Mutant                                                0                         4           
  *FGFR1* status                                                                               
   Wild-type                                             56                        135         0.065
   Mutant                                                0                         10          
  *PDGFRA* status                                                                              
   Wild-type                                             55                        144         0.481
   Mutant ^a^                                            1                         1           
  *KRAS* status                                                                                
   Wild-type                                             29                        97          0.047
   Mutant                                                27                        48          
  *NRAS* status                                                                                
   Wild-type                                             54                        142         0.620
   Mutant                                                2                         3           
  *HRAS* status                                                                                
   Wild-type                                             55                        143         0.999
   Mutant                                                1                         2           
  *BRAF* status                                                                                
   Wild-type                                             41                        136         \< 0.001
   Mutant                                                15                        9           
  *MAPK2K1* status                                                                             
   Wild-type                                             54                        137         0.729
   Mutant                                                2                         8           
  *PTEN* status                                                                                
   Wild-type                                             39                        107         0.554
   Mutant ^b^                                            17                        38          
  *PIK3CA* status                                                                              
   Wild-type                                             41                        127         0.014
   Mutant                                                15                        18          
  Alterations in TK receptors/RAS pathway/PI3K pathway                                         
   0                                                     6                         41          0.024
   1                                                     24                        56          
   2 or more                                             26                        48          
   All wild-type                                         6                         41          0.009
   Mutant-type                                           50                        104         

^a^ Including mutation and amplification.

^b^ Including mutation and deletion

Efficacy of anti-EGFR therapy according to primary tumor sidedness and genetic alterations associated with resistance to anti-EGFR therapy {#s2_3}
------------------------------------------------------------------------------------------------------------------------------------------

Among the 49 patients treated with anti-EGFR therapy in addition to cytotoxic chemotherapy, patients with RCRC showed significantly worse progression-free survival (PFS) than patients with LCRC (*P* = 0.022; Figure [4A](#F4){ref-type="fig"}). Regarding the 12 genes associated with anti-EGFR therapy resistance in these 49 patients, 18, 25, and 6 patients had 0, 1 and 2 genetic alterations, respectively. No significant difference was observed in PFS between "all wild-type" and "mutant-type" (Figure [4B](#F4){ref-type="fig"}), but the six patients with two genetic alterations showed significantly worse PFS than patients with no genetic mutations (*P* = 0.005; Figure [4C](#F4){ref-type="fig"}). After stratification by primary tumor sidedness, we found *BRAF* mutations were significantly associated with RCRC (*P* = 0.047; Table [4](#T4){ref-type="table"}). When the 49 patients were classified into four groups according to primary tumor sidedness and genetic alterations associated with anti-EGFR therapy resistance, "mutant-type" RCRC showed a significantly worse PFS compared with "all wild-type" LCRC (*P* = 0.004; Figure [4D](#F4){ref-type="fig"}).

![Progression-free survival of patients who received anti-EGFR therapy in addition to cytotoxic chemotherapy\
**(A)** Progression-free survival stratified by primary tumor sidedness. **(B)** Progression-free survival stratified by genetic alterations associated with resistance to anti-EGFR therapy. **(C)** Progression-free survival stratified by the number of genetic alterations associated with resistance to anti-EGFR therapy. **(D)** Progression-free survival stratified by primary tumor sidedness and genetic alterations. "All wild-type" indicates patients without any genetic alterations associated with resistance to anti-EGFR therapy, and "mutant-type" indicates those with one or more genetic alterations. RCRC, right-sided colorectal cancer; LCRC, left-sided colorectal cancer.](oncotarget-08-93567-g004){#F4}

###### Association between primary tumor sidedness and clinicopathological characteristics in 49 patients with anti-EGFR therapy in addition to cytotoxic chemotherapy

                                                                                               Primary tumor sidedness   *P*-value   
  -------------------------------------------------------------------------------------------- ------------------------- ----------- -------
  Age (years)                                                                                                                        
   \< 65                                                                                       4                         27          0.443
   ≥ 65                                                                                        4                         14          
  Sex                                                                                                                                
   Male                                                                                        4                         27          0.443
   Female                                                                                      4                         14          
  Tumor size (mm)                                                                                                                    
   \< 50                                                                                       5                         19          0.463
   ≥ 50                                                                                        3                         22          
  T category                                                                                                                         
   T2, 3                                                                                       4                         18          0.999
   T4                                                                                          4                         23          
  Histopathological grading                                                                                                          
   G1, 2                                                                                       3                         32          0.033
   G3                                                                                          5                         9           
  Lymphatic invasion                                                                                                                 
   Absence                                                                                     1                         14          0.406
   Presence                                                                                    7                         27          
  Venous invasion                                                                                                                    
   Absence                                                                                     2                         6           0.601
   Presence                                                                                    6                         35          
  N category                                                                                                                         
   N0                                                                                          1                         5           0.999
   N1, 2                                                                                       7                         36          
  M category                                                                                                                         
   M0                                                                                          1                         1           0.421
   M1a                                                                                         4                         23          
   M1b                                                                                         3                         17          
  *KRAS* status                                                                                                                      
   Wild-type                                                                                   7                         39          0.421
   Mutant                                                                                      1                         2           
  *BRAF* status                                                                                                                      
   Wild-type                                                                                   5                         38          0.047
   Mutant                                                                                      3                         3           
  Alterations in TK receptors/RAS pathway/PI3K pathway excluding *KRAS* and *BRAF* mutations                                         
   Absence                                                                                     7                         20          0.059
   Presence                                                                                    1                         21          
  Alterations in TK receptors/RAS pathway/PI3K pathway                                                                               
   0                                                                                           3                         15          0.492
   1                                                                                           5                         20          
   2                                                                                           0                         6           
   All wild-type                                                                               3                         15          0.999
   Mutant-type                                                                                 5                         26          
  Anti-EGFR drug                                                                                                                     
   Cetuximab                                                                                   2                         9           0.999
   Panitumumab                                                                                 6                         32          
  Anti-EGFR therapy                                                                                                                  
   Initial therapy                                                                             3                         9           0.386
   Subsequent therapy                                                                          5                         32          
  Chemotherapy added to anti-EGFR therapy                                                                                            
   Oxaliplatin-based                                                                           3                         7           0.195
   Irinotecan-based                                                                            3                         29          
   Anti-EGFR drug only                                                                         2                         5           

DISCUSSION {#s3}
==========

CGS analysis of genetic alterations in 201 primary CRCs revealed important genetic differences in relation to tumor sidedness: that there are genetic alterations in RCRC that are distinct from LCRC, and that CRCs wild-type in TK receptors and the RAS and PI3K pathways (termed "all wild-type" tumors and theoretically more likely to respond to anti-EGFR therapy), were significantly less common amongst RCRC. These genetic differences likely drive the inherent resistance of RCRCs to anti-EGFR therapy.

Primary tumor sidedness of CRC has prognostic importance and relates to response to targeted therapy \[[@R15]-[@R18]\]. Recent meta-analyses reported that RCRC was a negative prognostic variable independent of Tumor-Node-Metastasis (TNM) stage \[[@R16]\]. Furthermore, patients with *RAS* wild-type LCRC had significantly greater survival benefit from anti-EGFR therapy compared with anti-vascular endothelial growth factor (VEGF) therapy; and, conversely, RCRC had poor benefit from standard therapies including anti-EGFR therapy, but was associated with longer survival with anti-VEGF therapy \[[@R17], [@R18]\]. The National Comprehensive Cancer Network (NCCN) guidelines noted that cetuximab and panitumumab confer little, if any, benefit to patients with metastatic CRC if the primary tumor originated on the right side, and primary tumor sidedness is a surrogate for the non-random distribution of molecular subtypes \[[@R18]\]. However, the molecular background of RCRC and LCRC has not been fully elucidated, and it is still unclear why anti-EGFR therapy is less efficacious in patients with RCRC compared with patients with LCRC. Hence, we investigated genomic differences between RCRC and LCRC using CGS, focusing on identifying the mechanism driving the observed difference in response to anti-EGFR therapy.

CGS has been shown to detect numerous genetic alterations, including driver mutations, in many solid cancers \[[@R24], [@R25]\]. Mutations in the RAS pathway, such as *KRAS*, *NRAS*, and *BRAF*, are benchmarks to determine treatment strategies for patients with metastatic CRC. The NCCN guidelines state that all patients with metastatic CRC should have tumor tissue genotyped for *KRAS*, *NRAS*, and *BRAF* mutations, and patients with any known *KRAS* or *NRAS* mutation should not be treated with anti-EGFR therapy such as cetuximab and panitumumab \[[@R18]\]. In the present analysis, we assumed that genetic alterations in TK receptors, the RAS pathway, or the PI3K pathway are possible mechanisms underlying resistance to anti-EGFR therapy \[[@R22], [@R23]\]. We successfully detected genetic alterations, not only in the RAS pathway, but also among TK receptors and the PI3K pathway that may be associated with resistance to anti-EGFR therapy. Furthermore, patients with RCRC showed a significantly worse PFS than those with LCRC.

Cancer genome profiling seeks to enable precision medicine, modifying therapies based on the unique genomic changes inherent in the individual tumor of each patient. In the present analysis, we showed an association between tumor sidedness and gene mutations, which may explain the difference in efficacy of anti-EGFR therapy in RCRC compared with LCRC. The genomic background of RCRC as revealed by CGS is consistent with the results of previous meta-analyses \[[@R15]-[@R17]\] and the NCCN guidelines regarding the relevance of tumor sidedness \[[@R18]\]. However, we also demonstrated that approximately 10% of RCRC patients had the "all wild-type" phenotype with no mutations detected in TK receptors or the RAS or PI3K pathways, and therefore, theoretically, these patients would be considered as responders to anti-EGFR therapy despite having RCRC. As such, while we showed that RCRC commonly demonstrates a genomic profile associated with resistance to anti-EGFR therapy, we propose future analyses should focus on individual tumors rather than primary tumor sidedness to best facilitate precision medicine.

CGS has ability to detect numerous actionable mutations that can guide new treatment strategies. In this analysis, a novel finding was *PALB2* mutations occurring significantly more frequent in RCRC than LCRC. *PALB2* is a DNA maintenance gene, where the encoded protein binds to and colocalizes with BRCA2 in nuclear foci, and plays a role of tumor suppression \[[@R27]\]. In CRC, the significance of *PALB2* mutations has not been elucidated, and this is the first report regarding *PALB2* mutations in relation to CRC sidedness. *PALB2* mutations are considered to be actionable, and are a biomarker for response to Poly (ADP-ribose) polymerase (PARP) inhibitors in pancreatic ([ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT03140670) and prostatic ([ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT02952534) cancers. In this analysis, we found 8 of 56 (14%) RCRCs had *PALB2* mutations compared with 3 of 145 (2%) LCRCs. Thus, targeting PALB2 may represent a future treatment strategy for RCRC.

To the best of our knowledge, this is the first report describing a genomic overview of RCRC and LCRC using CGS. However, this analysis has several limitations. First, it was a retrospective analysis performed at two institutions and included a relatively small number of patients. Second, the selection of genomic biomarkers of resistance outside of *RAS* is not yet well supported by prospective studies. Third, as patients who received anti-EGFR therapy were analyzed retrospectively, we could not definitively associate primary tumor sidedness with response to anti-EGFR therapy. Fourth, as the number of RCRC patients who received anti-EGFR therapy was small, we need for increasing the number of RCRC patients in future. However, we did demonstrate that RCRC was significantly associated with genetic alterations associated with resistance to anti-EGFR therapy, which provides a plausible mechanism of resistance to anti-EGFR therapy in patients with RCRC.

In conclusion, we show RCRC is more likely to harbor genetic alterations associated with resistance to anti-EGFR therapy compared with LCRC, and primary tumor sidedness is a surrogate for a non-random distribution of genetic alterations in CRC.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

This retrospective analysis was performed in accordance with the Helsinki Declaration and the protocol was approved by the Ethics Committee of the School of Medicine, Niigata University. We randomly selected and enrolled 201 patients diagnosed with stage I - IV CRC based on the 7^th^ edition of the American Joint Committee on Cancer staging manual \[[@R28]\] who had a primary tumor resection between 2009 and 2015 at Niigata University Medical and Dental Hospital or Niigata Cancer Center Hospital. In this analysis, we included the 201 independent individuals, all unrelated, confirmed from our database and medical charts. Patients with familial adenomatous polyposis or inflammatory bowel disease were excluded.

Primary tumor sidedness and clinicopathological characteristics {#s4_2}
---------------------------------------------------------------

Primary tumor location was determined by operative findings. Cancer in the cecum, ascending colon, hepatic flexure, or transverse colon was classified as right-sided; and cancer in the splenic flexure, descending colon, sigmoid colon, rectosigmoid, or rectum was classified as left-sided \[[@R29], [@R30]\]. Histopathological features associated with RCRC, such as medullary type, mucinous type, signet ring type, and tumor-infiltrating lymphocytes were analyzed by a previously reported method \[[@R31]\]. MutL homologue 1 (MLH1)/MutS homologue 2 (MSH2) status was evaluated in 110 of the 201 patients by immunohistochemistry with anti-MLH1 (1:50; BD Biosciences PharMingen, San Diego, CA) and anti-MSH2 (1:50; Leica Microbiosystems, Tokyo, Japan) antibodies. Hypermutation was defined as a tumor with MSI-H and/or high tumor mutation burden (TMB), as described previously \[[@R25]\], using CGS. TMB was calculated as the number of non-synonymous mutations per megabase of sequence in the panel (panel size = 1.3 Mb). To be classified as hypermutated, the threshold of TMB was set as the lowest TMB observed in tumors with MSI-H. Tumors with mutations in *POLE* or other DNA repair genes can have very high TMB but not show MSI-H \[[@R25]\].

CGS analysis of primary tumors {#s4_3}
------------------------------

Archival tissue in the form of formalin-fixed, paraffin-embedded (FFPE) tumor or unstained tissue sections obtained during primary tumor resection were used for CGS. An independent pathologist evaluated tumor content in each sample using hematoxylin and eosin-stained slides to ensure \> 50% tumor content was present. Where applicable, unstained slides were macro-dissected to enrich for tumor content and DNA was extracted using a BioStic FFPE Tissue DNA Isolation Kit (Mo Bio Laboratories, Inc., Carlsbad, CA). All sample preparation, CGS, and analytics were performed in a CLIA/CAP-accredited laboratory (KEW Inc., Cambridge, MA). DNA fragment (50--150 ng) libraries were prepared and enriched for the CancerPlex 415-gene panel (KEW Inc.) \[[@R25], [@R26]\], a large clinically validated panel of 415 genes enriched for coding regions and selected introns of known cancer-related genes. Sequencing was performed on Illumina MiSeq and NextSeq platforms with an average 500× sequencing depth. Genomic data were then processed through a proprietary bioinformatics platform and knowledgebase to identify multiple classes of genomic abnormalities including single nucleotide substitutions, small insertions/deletions, copy number variations, and translocations. Single nucleotide variant (SNV) and insertion or deletion (indel) calling were only performed in genomic regions intended to be captured by the assay (region of interest). We set a standard threshold of 10% allelic fraction for calling SNVs and indels to focus on primary truncal driver mutations and avoid subclonal events. Copy number variants were called for exons as well as globally. We segmented regions using a Fused-Lasso method and export the results to a VCF file. The threshold for gain was \> 2.5 fold and for loss was \< 0.5 fold. Variants were filtered or flagged according to technical quality (e.g. coverage, allelic fraction, number of supporting reads), presence in previously characterized normal samples, or presence/absence in the following databases: dbSNP, ExAC, COSMIC, ClinVar, and KEW. SNVs and indels in VCF format were annotated using SnpEff and the output was adapted according to HGVS recommendations \[[@R25], [@R26]\].

Genetic alterations in TK receptors and the RAS and PI3K pathways in RCRC and LCRC {#s4_4}
----------------------------------------------------------------------------------

Genetic alterations of TK receptors (*ERBB2*, *MET*, *EGFR*, *FGFR1*, and *PDGFRA*), RAS pathway (*KRAS*, *NRAS*, *HRAS*, *BRAF*, and *MAPK2K1*), and PI3K pathway (*PTEN* and *PIK3CA*) were analyzed using CGS of the 415-gene panel. We defined patients who had no alterations in all 12 genes as "all wild-type"; theoretically, these patients should respond to anti-EGFR therapy \[[@R22], [@R23]\]. We defined the remaining patients with genetic alterations as "mutant-type". We also estimated the incidence of "all wild-type" for RCRC and LCRC. In this analysis of 201 patients, 49 received anti-EGFR therapy. In these 49 patients, we investigated the efficacy of anti-EGFR therapy according to primary tumor sidedness and genetic alterations associated with resistance to anti-EGFR therapy.

Statistical analysis {#s4_5}
--------------------

Statistical analyses were performed with IBM SPSS Statistics 22 (IBM Japan, Inc., Tokyo, Japan). A Fisher's exact test or Chi-squared test was used to evaluate associations between primary tumor sidedness and clinicopathological characteristics, and primary tumor sidedness and genetic alterations were evaluated with CGS. The association between primary tumor sidedness and genetic alterations associated with resistance to anti-EGFR therapy was examined by Fisher's exact test or Chi-squared test. PFS rates in patients treated with anti-EGFR therapy (cetuximab or panitumumab) in addition to cytotoxic chemotherapy were estimated using Kaplan-Meier analysis. A log-rank test was used to assess for a significant difference between right-sided and left-sided tumors. *P*-values \< 0.05 were considered statistically significant.
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